CompanyPLURNasdaqHaifa

Pluri Inc.

Pluri develops a proprietary 3D cell expansion platform for scalable human, plant, and animal cell manufacturing.

SEC EDGAR ClinicalTrials.gov pluri-biotech.com

8-KSep 29Latest SEC filing

Sep 4Latest story

September 2026

Pluri prices $1.50 registered offering, plans concurrent private placement warrants

Sep 4FinancingPluri Inc.

August 2026

Pluri Inc. discloses terms of $2.98 million registered direct offering

Aug 28PartnershipPluri Inc.